Iterum Therapeutics plc (ITRM)
NASDAQ: ITRM · Real-Time Price · USD
1.490
0.00 (0.00%)
At close: Feb 21, 2025, 4:00 PM
1.520
+0.030 (2.01%)
After-hours: Feb 21, 2025, 5:56 PM EST
Iterum Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Cost of Revenue | 0.25 | - | - | - | - | |
| Gross Profit | -0.25 | - | - | - | - | |
| Selling, General & Admin | 7.98 | 7.48 | 12.77 | 13.83 | 11.05 | |
| Research & Development | 10.46 | 39.99 | 17.62 | 10.71 | 21.07 | |
| Operating Expenses | 18.44 | 47.47 | 30.38 | 24.54 | 32.13 | |
| Operating Income | -18.7 | -47.47 | -30.38 | -24.54 | -32.13 | |
| Interest Expense | -2.52 | -1.43 | -2.36 | -4.53 | -12.3 | |
| Other Non Operating Income (Expenses) | -3.32 | 11.14 | -11.39 | -61.79 | -7.18 | |
| EBT Excluding Unusual Items | -24.53 | -37.76 | -44.13 | -90.86 | -51.6 | |
| Other Unusual Items | - | - | - | - | 0.34 | |
| Pretax Income | -24.53 | -37.76 | -44.13 | -90.86 | -51.26 | |
| Income Tax Expense | 0.24 | 0.61 | 0.3 | 0.71 | 0.74 | |
| Net Income | -24.77 | -38.37 | -44.43 | -91.56 | -52.01 | |
| Net Income to Common | -24.77 | -38.37 | -44.43 | -91.56 | -52.01 | |
| Shares Outstanding (Basic) | 20 | 13 | 12 | 11 | 2 | |
| Shares Outstanding (Diluted) | 20 | 13 | 12 | 11 | 2 | |
| Shares Change (YoY) | 51.97% | 5.93% | 12.35% | 580.42% | 65.38% | |
| EPS (Basic) | -1.26 | -2.96 | -3.63 | -8.41 | -32.49 | |
| EPS (Diluted) | -1.26 | -2.96 | -3.63 | -8.41 | -32.49 | |
| Free Cash Flow | -26.77 | -39.34 | -18.54 | -15.9 | -54.54 | |
| Free Cash Flow Per Share | -1.36 | -3.04 | -1.51 | -1.46 | -34.07 | |
| EBITDA | -18.41 | -45.72 | -28.58 | -22.43 | -31.97 | |
| D&A For EBITDA | 0.28 | 1.75 | 1.8 | 2.1 | 0.16 | |
| EBIT | -18.7 | -47.47 | -30.38 | -24.54 | -32.13 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.